Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus IBUPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus IBUPROFEN SODIUM.
DYLOJECT vs IBUPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Category C
Category D/X
NSAID
NSAID